GlassScriptPhysician profile
Emi Harris
NPI 1134769573
$4,478.89
in general payments reported to CMS, 2019-2025
37 companies · $2,221 in 2025
The $2,221 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $255 · 2022: $558 · 2023: $462 · 2024: $982 · 2025: $2,221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,269 · Education: $367 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $30.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,268.74 |
| Education | $366.93 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $30.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $809.96 | 2022-2025 | Darzalex, Tecvayli, Talvey |
| Abbvie INC. | $564.24 | 2023-2025 | |
| Celgene Corporation | $234.50 | 2021-2025 | Reblozyl, Opdivo, Pomalyst |
| Astrazeneca Pharmaceuticals LP | $217.53 | 2022-2025 | |
| Pfizer INC. | $212.07 | 2024-2025 | |
| Tersera Therapeutics LLC | $203.55 | 2023-2025 | Zoladex, Xermelo |
| E.R. Squibb & Sons, L.L.C. | $194.02 | 2023-2025 | Reblozyl, Opdivo |
| Genmab U.S., INC. | $181.21 | 2023-2025 | Epkinly |
| Merck Sharp & Dohme LLC | $170.29 | 2023-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Incyte Corporation | $140.39 | 2021-2025 | Monjuvi |
| Pharmaessentia USA Corporation | $130.26 | 2025 | Besremi |
| Karyopharm Therapeutics INC. | $117.62 | 2022 | |
| Genentech USA, INC. | $115.01 | 2025 | Phesgo, Venclexta |
| Jazz Pharmaceuticals INC. | $104.23 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $99.95 | 2022 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emi Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.